WO2009126789A3 - Engineering and delivery of therapeutic compositions of freshly isolated cells - Google Patents

Engineering and delivery of therapeutic compositions of freshly isolated cells Download PDF

Info

Publication number
WO2009126789A3
WO2009126789A3 PCT/US2009/040040 US2009040040W WO2009126789A3 WO 2009126789 A3 WO2009126789 A3 WO 2009126789A3 US 2009040040 W US2009040040 W US 2009040040W WO 2009126789 A3 WO2009126789 A3 WO 2009126789A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
engineering
delivery
therapeutic compositions
isolated cells
Prior art date
Application number
PCT/US2009/040040
Other languages
French (fr)
Other versions
WO2009126789A2 (en
Inventor
Linhong Li
Madhusudan V. Peshwa
Original Assignee
Maxcyte, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxcyte, Inc. filed Critical Maxcyte, Inc.
Priority to DK09731422.3T priority Critical patent/DK2279253T3/en
Priority to JP2011504171A priority patent/JP5779090B2/en
Priority to EP09731422.3A priority patent/EP2279253B1/en
Publication of WO2009126789A2 publication Critical patent/WO2009126789A2/en
Publication of WO2009126789A3 publication Critical patent/WO2009126789A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/464468—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.
PCT/US2009/040040 2008-04-09 2009-04-09 Engineering and delivery of therapeutic compositions of freshly isolated cells WO2009126789A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DK09731422.3T DK2279253T3 (en) 2008-04-09 2009-04-09 Construction and application of therapeutic compositions of freshly isolated cells
JP2011504171A JP5779090B2 (en) 2008-04-09 2009-04-09 Manipulation and delivery of therapeutic compositions of newly isolated cells
EP09731422.3A EP2279253B1 (en) 2008-04-09 2009-04-09 Engineering and delivery of therapeutic compositions of freshly isolated cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4365308P 2008-04-09 2008-04-09
US61/043,653 2008-04-09

Publications (2)

Publication Number Publication Date
WO2009126789A2 WO2009126789A2 (en) 2009-10-15
WO2009126789A3 true WO2009126789A3 (en) 2010-01-28

Family

ID=41162602

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/040040 WO2009126789A2 (en) 2008-04-09 2009-04-09 Engineering and delivery of therapeutic compositions of freshly isolated cells

Country Status (5)

Country Link
US (8) US8450112B2 (en)
EP (1) EP2279253B1 (en)
JP (4) JP5779090B2 (en)
DK (1) DK2279253T3 (en)
WO (1) WO2009126789A2 (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
WO2008097926A2 (en) * 2007-02-02 2008-08-14 Yale University Transient transfection with rna
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
JP5779090B2 (en) * 2008-04-09 2015-09-16 マックスサイト インコーポレーティッド Manipulation and delivery of therapeutic compositions of newly isolated cells
LT2649086T (en) * 2010-12-09 2017-11-10 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP5572863B2 (en) * 2011-06-24 2014-08-20 国立大学法人九州大学 Method for amplifying NK cells
JP5989016B2 (en) * 2011-06-24 2016-09-07 国立大学法人九州大学 Method for amplifying NK cells
CA2848410A1 (en) 2011-09-16 2013-03-21 The Trustees Of The University Of Pennsylvania Rna engineered t cells for the treatment of cancer
WO2013063419A2 (en) * 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
US9359447B2 (en) 2012-03-23 2016-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
ES2867224T3 (en) * 2014-04-10 2021-10-20 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Transgenic genetic labels and methods of use
WO2016095934A2 (en) * 2014-12-14 2016-06-23 El Abd Hisham Mohamed Magdy A novel genetic device to engineer cell behavior
AU2016211161C1 (en) 2015-01-30 2023-11-23 The Regents Of The University Of California Protein delivery in primary hematopoietic cells
US11059880B2 (en) 2015-06-30 2021-07-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with MHC chimeric receptors and methods of use in immunotherapy
US11034749B2 (en) 2015-07-28 2021-06-15 The Trustees Of The University Of Pennsylvania Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
CA2994829A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
US11400145B2 (en) 2015-11-27 2022-08-02 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN110582288A (en) 2017-02-28 2019-12-17 恩多塞特公司 Compositions and methods for CAR T cell therapy
EP3612210A4 (en) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
KR20220104847A (en) 2017-06-30 2022-07-26 인스크립타 인코포레이티드 Automated cell processing methods, modules, instruments, and systems
JP2020530280A (en) * 2017-07-03 2020-10-22 トルク セラピューティクス， インコーポレイテッド Immunostimulatory fusion molecule and its use
US10738327B2 (en) 2017-08-28 2020-08-11 Inscripta, Inc. Electroporation cuvettes for automation
WO2019068022A1 (en) 2017-09-30 2019-04-04 Inscripta, Inc. Flow through electroporation instrumentation
WO2019090355A1 (en) * 2017-11-06 2019-05-09 Children's National Medical Center Cells expressing antibodies and methods of treatment using the same
EP3735255A4 (en) * 2018-01-05 2021-09-22 Maxcyte, Inc. Chronic car treatment for cancer
JP7417542B2 (en) 2018-01-22 2024-01-18 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） How to use CAR T cells
MA51792A (en) * 2018-02-09 2020-12-16 Immatics Us Inc T LYMPHOCYTES MANUFACTURING PROCESSES
US10443031B1 (en) 2018-03-29 2019-10-15 Inscripta, Inc. Methods for controlling the growth of prokaryotic and eukaryotic cells
US10376889B1 (en) 2018-04-13 2019-08-13 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10557216B2 (en) 2018-04-24 2020-02-11 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
WO2019209926A1 (en) 2018-04-24 2019-10-31 Inscripta, Inc. Automated instrumentation for production of peptide libraries
CN114854720A (en) 2018-06-30 2022-08-05 因思科瑞普特公司 Apparatus, modules and methods for improved detection of editing sequences in living cells
US10532324B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
WO2020051493A1 (en) * 2018-09-07 2020-03-12 Unum Therapeutics Inc. Chimeric receptor polypeptides in combination with trans metabolism molecules modulating intracellular lactate concentrations and therapeutic uses thereof
CA3115534A1 (en) 2018-10-22 2020-04-30 Inscripta, Inc. Engineered nucleic acid-guided nucleases
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
CN111349615A (en) * 2018-12-24 2020-06-30 上海细胞治疗集团有限公司 Method for preparing cell over expressing exogenous gene
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
CA3134168A1 (en) 2019-03-25 2020-10-01 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
CA3139122C (en) 2019-06-06 2023-04-25 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
EP3986909A4 (en) 2019-06-21 2023-08-02 Inscripta, Inc. Genome-wide rationally-designed mutations leading to enhanced lysine production in e. coli
US10927385B2 (en) 2019-06-25 2021-02-23 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
WO2021118626A1 (en) 2019-12-10 2021-06-17 Inscripta, Inc. Novel mad nucleases
US10704033B1 (en) 2019-12-13 2020-07-07 Inscripta, Inc. Nucleic acid-guided nucleases
AU2020407048A1 (en) 2019-12-18 2022-06-09 Inscripta, Inc. Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
US10689669B1 (en) 2020-01-11 2020-06-23 Inscripta, Inc. Automated multi-module cell processing methods, instruments, and systems
WO2021154706A1 (en) 2020-01-27 2021-08-05 Inscripta, Inc. Electroporation modules and instrumentation
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
CA3184807A1 (en) 2020-06-04 2021-12-09 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
EP4214314A1 (en) 2020-09-15 2023-07-26 Inscripta, Inc. Crispr editing to embed nucleic acid landing pads into genomes of live cells
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
US11306298B1 (en) 2021-01-04 2022-04-19 Inscripta, Inc. Mad nucleases
EP4274890A1 (en) 2021-01-07 2023-11-15 Inscripta, Inc. Mad nucleases
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2024059618A2 (en) 2022-09-13 2024-03-21 Arsenal Biosciences, Inc. Immune cells having co-expressed tgfbr shrnas
WO2024059824A2 (en) 2022-09-16 2024-03-21 Arsenal Biosciences, Inc. Immune cells with combination gene perturbations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024671A1 (en) * 1995-02-06 1996-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US20030026790A1 (en) * 2001-03-09 2003-02-06 Patrick Hwu Activated dual specificity lymphocytes and their methods of use
WO2008097926A2 (en) * 2007-02-02 2008-08-14 Yale University Transient transfection with rna

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4228457A1 (en) 1992-08-27 1994-04-28 Beiersdorf Ag Production of heterodimeric PDGF-AB using a bicistronic vector system in mammalian cells
EP1466968A3 (en) 1993-03-23 2006-10-04 Cbr Laboratories, Inc. Method and apparatus for encapsulation of biologically-active substances
FR2722208B1 (en) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med NEW INTERNAL RIBOSOME ENTRY SITE, VECTOR CONTAINING SAME AND THERAPEUTIC USE
US6074605A (en) * 1995-03-10 2000-06-13 Entremed, Inc. Flow electroporation chamber and method
US6773669B1 (en) 1995-03-10 2004-08-10 Maxcyte, Inc. Flow electroporation chamber and method
US5720921A (en) 1995-03-10 1998-02-24 Entremed, Inc. Flow electroporation chamber and method
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US6090617A (en) * 1996-12-05 2000-07-18 Entremed, Inc. Flow electroporation chamber with electrodes having a crystalline metal nitride coating
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
ATE338124T1 (en) 2000-11-07 2006-09-15 Hope City CD19-SPECIFIC TARGETED IMMUNE CELLS
US7029916B2 (en) * 2001-02-21 2006-04-18 Maxcyte, Inc. Apparatus and method for flow electroporation of biological samples
US7141425B2 (en) * 2001-08-22 2006-11-28 Maxcyte, Inc. Apparatus and method for electroporation of biological samples
US20040115784A1 (en) * 2002-09-30 2004-06-17 Maxcyte, Inc. Apparatus and method for streaming electroporation
WO2004074451A2 (en) * 2003-02-18 2004-09-02 Maxcyte, Inc. Loading of cells with antigens by electroporation
WO2006063301A1 (en) * 2004-12-10 2006-06-15 Maxcyte, Inc. Genetically modified tumor cells as cancer vaccines
EP1795599A1 (en) 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
EP2856876B1 (en) * 2007-03-30 2018-01-31 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
JP5779090B2 (en) * 2008-04-09 2015-09-16 マックスサイト インコーポレーティッド Manipulation and delivery of therapeutic compositions of newly isolated cells
KR101076879B1 (en) 2008-04-11 2011-10-25 주식회사 하이닉스반도체 Method of programming flash memory device using self boosting
WO2012050374A2 (en) 2010-10-13 2012-04-19 Innocell, Inc. Immunotherapy for solid tumors
LT2649086T (en) 2010-12-09 2017-11-10 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
ES2828982T3 (en) 2013-05-14 2021-05-28 Univ Texas Human application of engineered chimeric antigen receptor (car) t cells
ES2928000T3 (en) 2014-06-06 2022-11-14 Memorial Sloan Kettering Cancer Center Mesothelin-targeted chimeric antigen receptors and uses thereof
SG10202104509PA (en) 2016-03-19 2021-06-29 Exuma Biotech Corp Methods and compositions for transducing lymphocytes and regulated expansion thereof
EP3735255A4 (en) 2018-01-05 2021-09-22 Maxcyte, Inc. Chronic car treatment for cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024671A1 (en) * 1995-02-06 1996-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US20030026790A1 (en) * 2001-03-09 2003-02-06 Patrick Hwu Activated dual specificity lymphocytes and their methods of use
WO2008097926A2 (en) * 2007-02-02 2008-08-14 Yale University Transient transfection with rna

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAXEVANIX, C. ET AL.: "Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes", CANCER IMMUNOL IMMUNOTHERAPY., vol. 53, no. 10, October 2004 (2004-10-01), pages 893 - 903, XP009089635 *
COOPER, L.J. ET AL.: "Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.", BLOOD CELLS MOL DIS., vol. 33, no. 1, July 2004 (2004-07-01), pages 83 - 89, XP008133536 *
RABINOVICH, P.M. ET AL.: "Synthetic messenger RNA as a tool for gene therapy.", HUM GENE THER., vol. 17, no. 10, October 2006 (2006-10-01), pages 1027 - 1035, XP002489890 *
SERRANO, L.M. ET AL.: "Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy", BLOOD., vol. 107, no. 7, 1 April 2006 (2006-04-01), pages 2643 - 2652, XP008133535 *

Also Published As

Publication number Publication date
EP2279253B1 (en) 2016-11-16
EP2279253A4 (en) 2011-12-21
JP2020012000A (en) 2020-01-23
US8450112B2 (en) 2013-05-28
JP6944497B2 (en) 2021-10-06
US20090257991A1 (en) 2009-10-15
US9669058B2 (en) 2017-06-06
DK2279253T3 (en) 2017-02-13
JP2011517944A (en) 2011-06-23
US20140017213A1 (en) 2014-01-16
US20220265722A1 (en) 2022-08-25
US20200237825A1 (en) 2020-07-30
EP2279253A2 (en) 2011-02-02
US10660917B2 (en) 2020-05-26
JP2017184759A (en) 2017-10-12
JP2016005459A (en) 2016-01-14
US20180028567A1 (en) 2018-02-01
JP6630074B2 (en) 2020-01-15
US20160082045A1 (en) 2016-03-24
US11331344B2 (en) 2022-05-17
JP5779090B2 (en) 2015-09-16
US9132153B2 (en) 2015-09-15
US20170258837A1 (en) 2017-09-14
US20200330519A1 (en) 2020-10-22
WO2009126789A2 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
WO2009126789A3 (en) Engineering and delivery of therapeutic compositions of freshly isolated cells
MX2011003842A (en) Targeting of antigen presenting cells with immunonanotherapeutics .
PH12016502012A1 (en) Defined composition gene modified t-cell products
MX2019011514A (en) Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy.
MX2011003843A (en) Adjuvant incorporation in immunonanotherapeutics.
MX2020012742A (en) Method and compositions for cellular immunotherapy.
MX2011003846A (en) Nicotine immunonanotherapeutics.
WO2011005566A3 (en) Aptamer-targeted sirna to inhibit nonsense mediated decay
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2007118245A3 (en) Methods and compositions related to adenoassociated virus-phage particles
EP2496607A4 (en) Vault complexes for cytokine delivery
WO2008054466A3 (en) Delivery of biologically active materials using core-shell tecto (dendritic polymers)
WO2010129339A3 (en) Compositions and methods for enhancing antigen-specific immune responses
WO2011017143A3 (en) Compositions and methods of preparing alloreactive cytotoxic t cells
Davies et al. IL-15 has innate anti-tumor activity independent of NK and CD8 T cells
MX2009008413A (en) Treatment and prevention of neurodegenerative diseases using gene therapy.
MX2015007678A (en) Transmucosal delivery of glatiramer acetate.
WO2012075440A3 (en) Compositions and methods for delivering clonidine to a target tissue site
WO2023004367A3 (en) Engineered targeting compositions for endothelial cells of the central nervous system vasculature and methods of use thereof
WO2009070609A3 (en) Therapeutic targeting of il-6 using sirna in neutral liposomes
MX2016007950A (en) T cell receptor binding to alwgpdpaaa, derived from human pre-pro insulin (ppi) protein.
WO2007149493A3 (en) Restoration of hearing loss
MX2009008108A (en) Pharmaceutical composition comprising tramadol and ketoprofen.
Helm et al. Targeting c-MYC with T-cells
US9795660B2 (en) Id-protein targeted tumor cell vaccine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09731422

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011504171

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2009731422

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009731422

Country of ref document: EP